acetylphenylalanyl-prolyl-boroarginine has been researched along with mci 9038 in 7 studies
| Studies (acetylphenylalanyl-prolyl-boroarginine) | Trials (acetylphenylalanyl-prolyl-boroarginine) | Recent Studies (post-2010) (acetylphenylalanyl-prolyl-boroarginine) | Studies (mci 9038) | Trials (mci 9038) | Recent Studies (post-2010) (mci 9038) |
|---|---|---|---|---|---|
| 30 | 0 | 0 | 1,087 | 83 | 349 |
| Protein | Taxonomy | acetylphenylalanyl-prolyl-boroarginine (IC50) | mci 9038 (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Callas, DD; Fareed, J | 2 |
| Gustafsson, D; Lenfors, S | 1 |
| Verstraete, M | 1 |
| Harding, SR; Lyon, AW; Lyon, ME; Oosman, SN | 1 |
| Chesebro, JH; Grill, DE; Hassinger, NL; McBane, RD; Mruk, JS | 1 |
2 review(s) available for acetylphenylalanyl-prolyl-boroarginine and mci 9038
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
5 other study(ies) available for acetylphenylalanyl-prolyl-boroarginine and mci 9038
| Article | Year |
|---|---|
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |
Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Boron Compounds; Dose-Response Relationship, Drug; Endopeptidases; Enzyme Precursors; Fibrinolytic Agents; Heparin; Hirudins; Humans; Oligopeptides; Partial Thromboplastin Time; Pipecolic Acids; Prothrombin; Sulfonamides; Thrombin | 1996 |
New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
Topics: Animals; Antithrombins; Arginine; Batroxobin; Boron Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolysis; Injections, Intravenous; Male; Oligopeptides; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin | 1996 |
Evaluation of argatroban and DUP 714 as anticoagulants for blood gas, electrolyte and ionized calcium analyses.
Topics: Antithrombins; Arginine; Blood Gas Analysis; Boron Compounds; Calcium; Chemistry, Clinical; Electrolytes; Evaluation Studies as Topic; Humans; Hydrogen-Ion Concentration; Oligopeptides; Oximetry; Pipecolic Acids; Sulfonamides | 2000 |
Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
Topics: Angioplasty, Balloon; Animals; Anticoagulants; Arginine; Boron Compounds; Drug Evaluation, Preclinical; Hirudins; Oligopeptides; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Swine; Thrombin; Thrombosis | 2005 |